LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

Kezdőlap・Részvénylista・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Nyitva

3.71 5.1

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.48

Maximum

3.75

Fő mutatók
By Trading Economics
Bevétel	-136K -35M
Egy részvényre jutó nyereség	-0.503
Munkavállalók	106
EBITDA	-619K -38M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+98.86% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 4.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-34M 261M
Előző nyitás	-1.39
Előző zárás	3.71

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. jún. 11. 23:56 UTC

Event

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

2026. jún. 11. 23:56 UTC

Correlated Moves

ETF Constituents

Macro News

iShares MSCI Brazil ETF trades higher after President Trump's cancellation of military strikes against Iran, boosting global investor confidence.

2026. jún. 11. 23:56 UTC

News

Monster Beverage shares higher in after-market trading following Bernstein's initiation of coverage with a Market Perform rating. The stock has gained over four consecutive sessions.

2026. jún. 11. 23:52 UTC

Michigan Consumer Sentiment Report for June 2026 Forecasts Continued Decline at 46.0 Amid Economic Pressures and Inflation Concerns

2026. jún. 11. 23:52 UTC

Investors Await Key U.S. Building Permits Report Amid Cautious Market Sentiment Ahead of June 16 Release

2026. jún. 11. 23:52 UTC

Macro Event

News

Correlated Moves

The Australian Dollar has gained against the Singapore Dollar, supported by a slight decline in consumer inflation expectations and recent geopolitical developments.

2026. jún. 11. 23:51 UTC

News

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting concerns over inflation following a rise in the producer price index.

2026. jún. 11. 23:51 UTC

Correlated Moves

Lam Research Corp is rising in after-market trading, supported by a broader market rally and strong momentum near the upper end of its one-month trading range.

2026. jún. 11. 23:51 UTC

Correlated Moves

Costco Wholesale Corp shares are higher in after-market hours, supported by a rising Nasdaq 100 Index and positive sentiment in the consumer staples sector.

2026. jún. 11. 23:51 UTC

Trip.com Group Ltd is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain this movement.

2026. jún. 11. 23:51 UTC

ETF Constituents

Vanguard FTSE Europe ETF is trading lower in after-market hours, impacted by declines from holdings including HSBC and Diageo, despite a generally higher market.

2026. jún. 11. 23:51 UTC

Marriott International Inc. shares declined in after-market hours following Thursday's close, with no specific news identified to explain the movement.

2026. jún. 11. 23:51 UTC

PepsiCo Inc shares are higher in after-market hours, driven by a significant overall market trend. The stock remains below its 20-day moving average.

2026. jún. 11. 23:51 UTC

Lululemon Athletica is trading lower in after-market hours, reflecting a decline since Thursday's close. It reached a session low earlier in the session.

2026. jún. 11. 23:51 UTC

Correlated Moves

ETF Constituents

News

Social Media

SPDR S&P 500 ETF Trust rises in after-hours trading amid improved market sentiment and reduced geopolitical tensions in Iran, supported by strong performances from top holdings.

2026. jún. 11. 23:51 UTC

Correlated Moves

ETF Constituents

News

Social Media

Invesco QQQ Trust Series I rises after hours, supported by a Nasdaq 100 rally driven by technology stocks and easing inflation concerns.

2026. jún. 11. 23:51 UTC

ETF Constituents

Correlated Moves

Macro News

Global X Copper Miners ETF declines in after-market trading as top holdings BHP and Southern Copper Corporation show slight decreases.

2026. jún. 11. 23:51 UTC

Correlated Moves

Microchip Technology Inc is rising in after-market trading, reflecting broader market trends amid the European Central Bank's recent interest rate hike.

2026. jún. 11. 23:51 UTC

Social Media

Correlated Moves

Micron Technology is trading higher in after-market hours, supported by positive market trends and favorable social media sentiment ahead of upcoming earnings.

2026. jún. 11. 23:51 UTC

Correlated Moves

The Nasdaq 100 Index is higher today, continuing its upward trend. Initial jobless claims rose unexpectedly, but this has not impacted the index's momentum.

2026. jún. 11. 23:51 UTC

News

The United States Oil Fund LP is higher in after-market trading amid reports of explosions in Iran raising concerns over oil supply stability.

2026. jún. 11. 23:46 UTC

Intuitive Surgical Inc. shares are higher in after-market trading, advancing modestly since Thursday's close despite remaining below the 20-day moving average.

2026. jún. 11. 23:46 UTC

Oil (Brent) is trading roughly flat with no specific news identified. It remains 7.63% below its 20-day moving average, indicating weak performance.

2026. jún. 11. 23:46 UTC

ETF Constituents

Correlated Moves

The Vanguard FTSE Developed Markets ETF is trading higher in after-market hours, buoyed by the European Central Bank's interest rate hike and strong performances from SAP and BP.

2026. jún. 11. 23:42 UTC

Housing Starts Data Release on June 16, 2026 Expected at 1.44 Million Amid Mixed Economic Sentiment and Inflation Concerns

2026. jún. 11. 23:42 UTC

U.S. Import Prices Expected to Rise Amid Inflation Concerns and Geopolitical Tensions Ahead of June 16 Release

2026. jún. 11. 23:42 UTC

U.S. Export Prices Expected to Rise 1% MoM Amid Mixed Economic Sentiment and Geopolitical Tensions Ahead of June 16 Release

2026. jún. 11. 23:42 UTC

Market Awaits May Housing Starts Data Amid Economic Uncertainties and Rising Costs.

2026. jún. 11. 23:42 UTC

U.S. Building Permits Expected to Rise Slightly to 1.41 Million Amid Cautious Optimism Ahead of June Release

2026. jún. 11. 23:42 UTC

Macro News

ETF Constituents

Investor sentiment towards the Consumer Staples Select Sector SPDR Fund improves in after-market trading, buoyed by macro developments and strong performances from key holdings.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

98.86% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 7 USD 98.86%

Magas 10 USD

Alacsony 4 USD

7 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

7 ratings

Vétel

Tartás

Eladás

7 Wall Street elemző célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.